Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 2Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Edema 1Brain Neoplasms 1Brain Edema 1Astrocytoma 1

Interventions

Magnetic Resonance Spectroscopy 4Temozolomide 3Radiotherapy 2vocimagene amiretrorepvec 1gallium Ga 68 dotatate 1cabazitaxel 1Valproic Acid 1Trail Making Test 1Radiosurgery 1Radiation 1Proton Magnetic Resonance Spectroscopy 1Procarbazine 1OKN 007 1Neuropsychological Tests 1N(alpha)-(4-amino-4-deoxypteroyl)-N(delta)-hemiphthaloyl-L-ornithine 1Magnetic Resonance Imaging 1Isotretinoin 1Irinotecan 1Gadolinium DTPA 1Fluorescein 1Filgrastim 1Equipment and Supplies 1Drug Therapy 1DNA 1Corticotropin-Releasing Hormone 1Carboplatin 1Biopsy 12-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Astrocytoma × Corticotropin-Releasing Hormone × Clear all
NCT00226668 2008-01-03

XERECEPT® (hCRF) for Primary Glioma Patients Requiring Dexamethasone to Treat Peritumoral Brain Edema

Celtic Pharma Development Services

Phase 3 Withdrawn
120 enrolled
CNS

Astrocytoma, Brain Edema, Brain Neoplasms, Edema

Data powered by HemOnc (CC BY 4.0) Colophon âš¡